XML 39 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 26, 2025
Segment Reporting [Abstract] |
Segment Results | Detailed segment data for the three and nine-month periods ended September 26, 2025 and September 27, 2024 is as follows ($ in millions):
| Biotechnology |  | Life Sciences |  | Diagnostics |  | Other(a) |  | Total |  |  |  |
For the Three-Month Period Ended September 26, 2025: |  |  |  |  |  |  |  |  |  |  |  |  |
Sales | $ | 1,798 |  |  | $ | 1,792 |  |  | $ | 2,463 |  |  | $ | — |  |  | $ | 6,053 |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation | (38) |  |  | (47) |  |  | (101) |  |  | (3) |  |  | (189) |  |  |  |  |
Amortization of intangible assets | (231) |  |  | (154) |  |  | (48) |  |  | — |  |  | (433) |  |  |  |  |
Impairments(b) | (86) |  |  | — |  |  | (15) |  |  | — |  |  | (101) |  |  |  |  |
Other segment expenses(c) | (1,091) |  |  | (1,369) |  |  | (1,634) |  |  | (82) |  |  | (4,176) |  |  |  |  |
Operating profit | $ | 352 |  |  | $ | 222 |  |  | $ | 665 |  |  | $ | (85) |  |  | $ | 1,154 |  |  |  |  |
For the Three-Month Period Ended September 27, 2024: |  |  |  |  |  |  |  |  |  |  |  |  |
Sales | $ | 1,653 |  |  | $ | 1,782 |  |  | $ | 2,363 |  |  | $ | — |  |  | $ | 5,798 |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation | (36) |  |  | (44) |  |  | (95) |  |  | (2) |  |  | (177) |  |  |  |  |
Amortization of intangible assets | (218) |  |  | (147) |  |  | (49) |  |  | — |  |  | (414) |  |  |  |  |
Impairments(b) | — |  |  | (222) |  |  | — |  |  | — |  |  | (222) |  |  |  |  |
Other segment expenses(c) | (1,009) |  |  | (1,334) |  |  | (1,604) |  |  | (80) |  |  | (4,027) |  |  |  |  |
Operating profit (loss) | $ | 390 |  |  | $ | 35 |  |  | $ | 615 |  |  | $ | (82) |  |  | $ | 958 |  |  |  |  |
| Biotechnology |  | Life Sciences |  | Diagnostics |  | Other(a) |  | Total
For the Nine-Month Period Ended September 26, 2025: |  |  |  |  |  |  |  |  |
Sales | $ | 5,260 |  |  | $ | 5,249 |  |  | $ | 7,221 |  |  | $ | — |  |  | $ | 17,730 |
Less: |  |  |  |  |  |  |  |  |
Depreciation | (110) |  |  | (137) |  |  | (301) |  |  | (7) |  |  | (555) |
Amortization of intangible assets | (672) |  |  | (453) |  |  | (144) |  |  | — |  |  | (1,269) |
Impairments(b) | (101) |  |  | (432) |  |  | (15) |  |  | — |  |  | (548) |
Other segment expenses(c) | (3,053) |  |  | (4,043) |  |  | (4,824) |  |  | (250) |  |  | (12,170) |
Operating profit | $ | 1,324 |  |  | $ | 184 |  |  | $ | 1,937 |  |  | $ | (257) |  |  | $ | 3,188 |
For the Nine-Month Period Ended September 27, 2024: |  |  |  |  |  |  |  |  |
Sales | $ | 4,890 |  |  | $ | 5,297 |  |  | $ | 7,150 |  |  | $ | — |  |  | $ | 17,337 |
Less: |  |  |  |  |  |  |  |  |
Depreciation | (113) |  |  | (123) |  |  | (292) |  |  | (6) |  |  | (534) |
Amortization of intangible assets | (650) |  |  | (428) |  |  | (145) |  |  | — |  |  | (1,223) |
Impairments(b) | — |  |  | (222) |  |  | — |  |  | — |  |  | (222) |
Other segment expenses(c) | (2,950) |  |  | (4,021) |  |  | (4,712) |  |  | (237) |  |  | (11,920) |
Operating profit (loss) | $ | 1,177 |  |  | $ | 503 |  |  | $ | 2,001 |  |  | $ | (243) |  |  | $ | 3,438 |
(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. (b) For information on the impairments, refer to Note 8. (c) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. The following table presents identifiable assets as of September 26, 2025 and December 31, 2024 ($ in millions):
| September 26, 2025 |  | December 31, 2024
Identifiable assets: |  |  |
Biotechnology | $ | 37,296 |  |  | $ | 34,605 |
Life Sciences | 23,179 |  |  | 23,211 |
Diagnostics | 14,653 |  |  | 14,204 |
Other | 4,769 |  |  | 5,522 |
Total | $ | 79,897 |  |  | $ | 77,542 |
The following table presents capital expenditures for the three and nine-month periods ended September 26, 2025 and September 27, 2024 ($ in millions):
| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Capital expenditures: |  |  |  |  |  |  |
Biotechnology | $ | 94 |  |  | $ | 117 |  |  | $ | 255 |  |  | $ | 330 |
Life Sciences | 40 |  |  | 52 |  |  | 129 |  |  | 162 |
Diagnostics | 157 |  |  | 129 |  |  | 397 |  |  | 382 |
Other | 1 |  |  | — |  |  | 4 |  |  | 2 |
Total | $ | 292 |  |  | $ | 298 |  |  | $ | 785 |  |  | $ | 876 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration